Kalamazoo, Michigan, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable January 31, 2024 to shareholders of record at the close of business on December 29, 2023, representing an increase of 6.7% versus the prior year and previous quarter.
“We continue to deliver strong growth and solid financial performance, and aligning with our capital allocation strategy we are raising our dividend 6.7%,” said Kevin Lobo, Chair and Chief Executive Officer.
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$346.50 |
Daily Change: | -0.17 -0.05 |
Daily Volume: | 1,324,316 |
Market Cap: | US$132.090B |
March 04, 2025 March 03, 2025 January 28, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load